NRAS and melanoma: To assess clinical relevance, we examined melanoma chemosensitivity to our recently described small molecule Usp9x inhibitor (G9)39, 43 and detected moderately greater sensitivity in NRAS versus BRAF mutant lines (Fig. 1e).